<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332419</url>
  </required_header>
  <id_info>
    <org_study_id>CASE13219</org_study_id>
    <nct_id>NCT04332419</nct_id>
  </id_info>
  <brief_title>Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies</brief_title>
  <official_title>Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging in Patients Undergoing Selective Internal Radiation Therapy for Hepatic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the results of positron emission tomography/computer&#xD;
      tomography (PET/CT) to positron emission tomography/magnetic resonance imaging (PET/MRI) to&#xD;
      help determine any added advantage of one over the other in relation to a tumor which might&#xD;
      assist in further management plans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in this study will undergo PET/CT (standard imaging) and PET/MR (additional&#xD;
      imaging), within 6 hours after SIRT with Y-90 for palliative treatment of the liver&#xD;
      malignancy. Patients will be randomized to receive either of the imaging modalities first,&#xD;
      based on the availability of the imaging device, and less than 1 hour apart. Upon acquirement&#xD;
      and construction of PET/CT and PET/MR images, a software (MIM SurePlan LiverY90) would be&#xD;
      utilized for semi-automatic determination of the liver/tumor contours and calculation of the&#xD;
      Y-90 absorbed doses (Gy) in the regions of interest (including within tumor and background&#xD;
      liver outlines) using the Local Deposition Method.&#xD;
&#xD;
      The primary objective of this study is to assess the agreement between post-Y-90 RE absorbed&#xD;
      doses (Gy) in the liver tumor tissues based on PET/CT versus PET/MR imaging. This would&#xD;
      permit the comparison of Y-90 tumor absorbed doses, acquired from PET/MR, with the current&#xD;
      standard of care PET/CT imaging to verify the data consistency and to validate its&#xD;
      application for the prediction of tumor response to treatment.&#xD;
&#xD;
      The secondary objective of this study is to assess the agreement between post-Y-90 RE&#xD;
      absorbed doses (Gy) in the background liver tissues (surrounding tumors), based on PET/CT&#xD;
      versus PET/MR imaging. This would permit the comparison of Y-90 background liver absorbed&#xD;
      doses, acquired from PET/MR, with the current standard of care PET/CT imaging to verify the&#xD;
      data consistency and to validate its application for the prediction of dose toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Actual">September 21, 2020</completion_date>
  <primary_completion_date type="Actual">September 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues</measure>
    <time_frame>Post-op day 0, 1 hour apart</time_frame>
    <description>RDC between the two imaging modalities for post-Y-90 Radioembolization (RE) absorbed doses (Gy) in the liver tumor tissues The RDC is the minimum difference between the two measurements that can be considered a true difference, with 95% confidence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RDC Between the Two Imaging Modalities in Background Liver Tissues</measure>
    <time_frame>Post-op day 0, 1 hour apart</time_frame>
    <description>RDC between the two imaging modalities for post-Y-90 RE absorbed doses (Gy) in the background liver tissues&#xD;
The RDC is the minimum difference between the two measurements that can be considered a true difference, with 95% confidence.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hepatic Malignancies</condition>
  <arm_group>
    <arm_group_label>PET/CT &amp; PET/MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>Standard Imaging</description>
    <arm_group_label>PET/CT &amp; PET/MR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/MR</intervention_name>
    <description>Additional Imaging</description>
    <arm_group_label>PET/CT &amp; PET/MR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIRT with Y-90</intervention_name>
    <description>SIRT with Y-90 for palliative treatment of the liver malignancy.</description>
    <arm_group_label>PET/CT &amp; PET/MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has a liver malignancy and is scheduled for SIRT with Y-90; AND&#xD;
&#xD;
          -  The patient is an adult, self-competent, and able to provide informed consent to&#xD;
             participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient loses competence, has a condition that questions their ability to provide&#xD;
             informed consent independently (e.g. cannot communicate in English), or withdraws&#xD;
             consent to participate within any time in the study period; OR&#xD;
&#xD;
          -  The patient is not eligible to undergo MRI due to the presence of metal devices or&#xD;
             implants in their body; OR&#xD;
&#xD;
          -  Both imaging modalities cannot take place within 6 hours after Y-90 RE; OR&#xD;
&#xD;
          -  Both imaging modalities cannot take place within 1 hour apart from each other&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ram Gurajala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <results_first_submitted>July 30, 2021</results_first_submitted>
  <results_first_submitted_qc>September 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2021</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Team will be sharing study results but not IPD because of HIPAA regulations</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 10, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT04332419/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT04332419/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PET/CT &amp; PET/MR</title>
          <description>One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.&#xD;
PET/CT: Standard Imaging&#xD;
PET/MR: Additional Imaging&#xD;
SIRT with Y-90: SIRT with Y-90 for palliative treatment of the liver malignancy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PET/CT &amp; PET/MR</title>
          <description>One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.&#xD;
PET/CT: Standard Imaging&#xD;
PET/MR: Additional Imaging&#xD;
SIRT with Y-90: SIRT with Y-90 for palliative treatment of the liver malignancy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues</title>
        <description>RDC between the two imaging modalities for post-Y-90 Radioembolization (RE) absorbed doses (Gy) in the liver tumor tissues The RDC is the minimum difference between the two measurements that can be considered a true difference, with 95% confidence.</description>
        <time_frame>Post-op day 0, 1 hour apart</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PET/CT &amp; PET/MR</title>
            <description>One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.&#xD;
PET/CT: Standard Imaging&#xD;
PET/MR: Additional Imaging&#xD;
SIRT with Y-90: SIRT with Y-90 for palliative treatment of the liver malignancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues</title>
          <description>RDC between the two imaging modalities for post-Y-90 Radioembolization (RE) absorbed doses (Gy) in the liver tumor tissues The RDC is the minimum difference between the two measurements that can be considered a true difference, with 95% confidence.</description>
          <units>percent difference</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Tumors</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Tumors</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="12.7" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RDC Between the Two Imaging Modalities in Background Liver Tissues</title>
        <description>RDC between the two imaging modalities for post-Y-90 RE absorbed doses (Gy) in the background liver tissues&#xD;
The RDC is the minimum difference between the two measurements that can be considered a true difference, with 95% confidence.</description>
        <time_frame>Post-op day 0, 1 hour apart</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PET/CT &amp; PET/MR</title>
            <description>One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.&#xD;
PET/CT: Standard Imaging&#xD;
PET/MR: Additional Imaging&#xD;
SIRT with Y-90: SIRT with Y-90 for palliative treatment of the liver malignancy.</description>
          </group>
        </group_list>
        <measure>
          <title>RDC Between the Two Imaging Modalities in Background Liver Tissues</title>
          <description>RDC between the two imaging modalities for post-Y-90 RE absorbed doses (Gy) in the background liver tissues&#xD;
The RDC is the minimum difference between the two measurements that can be considered a true difference, with 95% confidence.</description>
          <units>percent difference</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>sessions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sessions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="18.5" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PET/CT &amp; PET/MR</title>
          <description>One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.&#xD;
PET/CT: Standard Imaging&#xD;
PET/MR: Additional Imaging&#xD;
SIRT with Y-90: SIRT with Y-90 for palliative treatment of the liver malignancy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ram Gurajala, MD</name_or_title>
      <organization>Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center</organization>
      <phone>1-866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

